NASDAQ:TRIB - Trinity Biotech Stock Price, News, & Analysis

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research industries. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.

Trinity Biotech (NASDAQ:TRIB) Frequently Asked Questions

What is Trinity Biotech's stock symbol?

Trinity Biotech trades on the NASDAQ under the ticker symbol "TRIB."

How were Trinity Biotech's earnings last quarter?

Trinity Biotech plc (NASDAQ:TRIB) announced its quarterly earnings data on Thursday, October, 26th. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.03. The company earned $25.60 million during the quarter, compared to analyst estimates of $25.52 million. Trinity Biotech had a negative net margin of 41.88% and a positive return on equity of 3.59%. View Trinity Biotech's Earnings History.

When is Trinity Biotech's next earnings date?

Trinity Biotech is scheduled to release their next quarterly earnings announcement on Tuesday, October 23rd 2018. View Earnings Estimates for Trinity Biotech.

Who are some of Trinity Biotech's key competitors?

Some companies that are related to Trinity Biotech include Nymox Pharmaceutical (NYMX), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Vermillion (VRML), Riot Blockchain (RIOT), Akers Biosciences (AKER), Achieve Life Sciences (ACHV), Arca Biopharma (ABIO), GeneNews (GNWSF), Fluoropharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN).

Who are Trinity Biotech's key executives?

Trinity Biotech's management team includes the folowing people:

• Mr. Ronan O'Caoimh, Co-Founder, Chairman & CEO (Age 62)
• Mr. Kevin Tansley, CFO, Company Sec. & Exec. Director (Age 47)
• Dr. James Walsh, Exec. Director (Age 60)

How do I buy shares of Trinity Biotech?

Shares of TRIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trinity Biotech's stock price today?

One share of TRIB stock can currently be purchased for approximately $3.41.

How big of a company is Trinity Biotech?

Trinity Biotech has a market capitalization of $73.88 million and generates $99.14 million in revenue each year. Trinity Biotech employs 556 workers across the globe.

What is Trinity Biotech's official website?

The official website for Trinity Biotech is http://www.trinitybiotech.com.

How can I contact Trinity Biotech?

Trinity Biotech's mailing address is IDA BUSINESS PARK BRAY, WICKLOW L2, . The company can be reached via phone at 353-1276-9800 or via email at [email protected]